As reported in John Carrol's EndPoint News early last month, GlobalData has published a list of the Top 20 Pharmaceutical Companies by market cap as of March 31, 2019. Notable advances include Takeda (up 142% based in part on its Shire acquisition, and jumping in the rankings from 23rd to 17th Q4 2018 – Q1 2019), with several other companies showing robust growth (including Celgene Corp., 37%; Novo Nordisk AS, 17%; Novartis AG, 14%; and Merck KGa, 13%; Hoffmann-La Roche, 12.7%). Companies declining included Bristol-Myers Squibb, 7.9%; Pfizer, 6.9%; and Bayer AG 4.9%. Biogen, the article notes, fell out of the Top 20. Expected acquisitions are expected to change this landscape again in the next several months.
